Amgen (NASDAQ: AMGN) withdraws listing for 2.000% Senior Notes due 2026

Rhea-AI Filing Summary

Amgen Inc. notified Nasdaq of the voluntary withdrawal of the 2.000% Senior Notes due 2026 from listing and registration. Nasdaq Stock Market LLC certified it has complied with applicable rules under 17 CFR 240.12d2-2 and the issuer has followed the Exchange's withdrawal requirements.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

000-12477

Issuer:	AMGEN INC
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	One Amgen Center Drive,
	Thousand Oaks	CALIFORNIA	91320-1799
Telephone number:					+1 805 447-1000

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

2.000% Senior Notes due 2026

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-02-24	By	Tara Petta		Director
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amgen (AMGN) file with the SEC regarding the 2026 notes?

Amgen filed a Form 25 to withdraw the listing of its 2.000% Senior Notes due 2026. Nasdaq certified compliance with 17 CFR 240.12d2-2 and the issuer certified it followed the Exchange's withdrawal procedures, indicating a voluntary delisting action.

Does the Form 25 mean Amgen redeemed or paid the notes?

No—Form 25 only notifies removal from listing and/or registration. The filing certifies procedural compliance for withdrawal under Nasdaq rules; it does not state whether notes were redeemed, repurchased, or otherwise settled in cash.

Who certified the withdrawal of Amgen's 2.000% Senior Notes due 2026?

Nasdaq Stock Market LLC certified the Form 25 filing and Amgen certified compliance with exchange rules. The submission names Nasdaq's authorized representative and cites specific provisions of 17 CFR 240.12d2-2 governing voluntary withdrawals.

Will the notes still exist after removal from Nasdaq listing?

Removal from Nasdaq listing does not by itself extinguish the notes. The Form 25 addresses exchange listing and registration status; the filing does not state the notes were redeemed or cancelled, nor does it specify subsequent trading venues.